Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Products under Development by Stage of Development | 8 | 1 |
| Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Products under Development by Therapy Area | 9 | 1 |
| Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Products under Development by Indication | 10 | 2 |
| Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Products under Development by Companies | 14 | 4 |
| Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Products under Development by Universities/Institutes | 18 | 2 |
| Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Therapeutics Assessment | 20 | 5 |
| Assessment by Monotherapy/Combination Products | 20 | 1 |
| Assessment by Mechanism of Action | 21 | 1 |
| Assessment by Route of Administration | 22 | 2 |
| Assessment by Molecule Type | 24 | 1 |
| Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Companies Involved in Therapeutics Development | 25 | 10 |
| 4SC AG | 25 | 1 |
| Chipscreen Biosciences Ltd | 26 | 1 |
| Curis, Inc. | 27 | 1 |
| GlaxoSmithKline Plc | 28 | 1 |
| HitGen LTD | 29 | 1 |
| IRBM Science Park SpA | 30 | 1 |
| Merck &Co., Inc. | 31 | 1 |
| Sigma-Tau S.p.A. | 32 | 1 |
| Syndax Pharmaceuticals, Inc. | 33 | 1 |
| TetraLogic Pharmaceuticals | 34 | 1 |
| Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Drug Profiles | 35 | 31 |
| 4SC-202 Drug Profile | 35 | 3 |
| chidamide Drug Profile | 38 | 3 |
| CUDC-907 Drug Profile | 41 | 5 |
| Drug to Inhibit HDAC-3 for Oncology Drug Profile | 46 | 1 |
| entinostat Drug Profile | 47 | 7 |
| HG-3001 Drug Profile | 54 | 1 |
| Largazole Drug Profile | 55 | 1 |
| N-140 Drug Profile | 56 | 1 |
| remetinostat Drug Profile | 57 | 2 |
| Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma Drug Profile | 59 | 1 |
| Small Molecule to Inhibit Histone Deacetylases for Oncology Drug Profile | 60 | 1 |
| ST-3595 Drug Profile | 61 | 1 |
| vorinostat Drug Profile | 62 | 4 |
| Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Dormant Projects | 66 | 3 |
| Histone Deacetylase 3 (SMAP45 or EC 3.5.1.98) Featured News &Press Releases | 69 | 11 |
| Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association | 69 | 1 |
| Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting | 69 | 1 |
| May 18, 2016: Entinostat Data to be Highlighted at the American Society of Clinical Oncology 2016 Annual Meeting | 69 | 1 |
| Apr 11, 2016: Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting | 70 | 1 |
| Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting | 71 | 1 |
| Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology | 72 | 1 |
| Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer | 72 | 1 |
| Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team | 73 | 1 |
| Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan | 74 | 1 |
| Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting | 74 | 2 |
| Dec 03, 2015: Syndax Announces Multiple Data Presentations on Entinostat at Upcoming San Antonio Breast Cancer Symposium | 76 | 1 |
| Dec 01, 2015: Syndax Announces Initiation Of Entinostat Clinical Program In Japan By Partner Kyowa Hakko Kirin | 77 | 1 |
| Nov 05, 2015: Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting | 77 | 1 |
| Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata | 78 | 1 |
| Sep 30, 2015: 4SC receives funding from the Eurostars programme for further research of its anti-cancer agent 4SC-202 with an epigenetic mode of action | 78 | 2 |
| Appendix | 80 | 2 |
| Methodology | 80 | 1 |
| Coverage | 80 | 1 |
| Secondary Research | 80 | 1 |
| Primary Research | 80 | 1 |
| Expert Panel Validation | 80 | 1 |
| Contact Us | 80 | 1 |
| Disclaimer | 81 | 1 |